Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label randomised controlled study in elderly subjects with previously untreated acute myelogenous leukaemia [acute myeloid leukaemia], comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833 [valspodar].

X
Trial Profile

An open label randomised controlled study in elderly subjects with previously untreated acute myelogenous leukaemia [acute myeloid leukaemia], comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833 [valspodar].

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valspodar (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 08 May 2012 Additional lead trial centers identified as reported by Netherlands Trial Register.
    • 08 May 2012 Additional trial location added as reported by Netherlands Trial Register.
    • 08 May 2012 New source identified and integrated (NTR360: Netherlands Trial Register).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top